Blinatumomab is a monoclonal bispecific T cell-engaging antibody that targets CD3 on T cells and CD19 on B cells, and it has become a key agent for the management of pediatric acute lymphoblastic leukemia (ALL) due to its high response rates and reduced hematologic toxicity compared to conventional chemotherapy. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.